METHODS FOR TREATING OPHTHALMOLOGICAL CONDITIONS
The present invention relates to methods for treating a subject with risk factors for progression to iRORA, iRORA, nGA, cRORA, GA, AMD, intermediate AMD, dry AMD, and/or wet AMD, in a subject in need thereof comprising administration of an effective amount of an anti-C 5 agent or a pharmaceutically acceptable salt thereof. The present invention also relates to methods for treating an ophthalmological disease, disorder, and/or condition in a subject with high-risk drusen, comprising administration of an effective amount of an anti-C 5 agent or a pharmaceutically acceptable salt thereof.
1 . A method for treating an ophthalmological disease, disorder, and/or condition comprising intravitreally administering a pegylated anti-C5 agent at a dose of about 2 mg/eye to a subject in need thereof having: (i) high-risk drusen and (ii) an ophthalmological disease, disorder, and/or condition selected from the group consisting of risk factors for the progression to iRORA, iRORA, nGA, cRORA, GA, AMD, intermediate AMD, dry AMD, and wet AMD,
wherein the pegylated anti-C5 agent is an Aptamer, wherein the Aptamer=fCmGfCfCGfCmGmGfUfCfUfCmAmGmGfCGfCfUmGmAmGfJfCfUmGmAmGfUfUfUAfCf CfUmGfCmG-3T (SEQ ID NO: 1), wherein fC and fU=2′ fluoro nucleotides, mG and mA=2′-OMe nucleotides, all other nucleotides are 2′-OH, and 3T indicates an inverted deoxythymidine.
or a salt thereof.
3 . The method of claim 1 , wherein the subject has intermediate AMD.
4 . The method of claim 1 , wherein the subject has iRORA.
5 . The method of claim 1 , wherein the subject has cRORA
6 . The method of claim 1 , wherein the subject has nGA.
7 . The method of claim 1 , wherein the subject has GA.
8 . A method for treating an ophthalmological disease, disorder, and/or condition selected from the group consisting of risk factors for the progression to iRORA, iRORA, nGA, cRORA, GA, AMD, intermediate AMD, dry AMD, and wet AMD, comprising intravitreally administering a pegylated anti-C5 agent at a dose of about 2 mg/eye to a subject in need thereof, wherein the subject has high-risk drusen,
wherein the pegylated anti-C5 agent is an Aptamer, wherein the Aptamer=fCmGfCfCGfCmGmGfUfCfUfCmAmGmGfCGfCfUmGmAmGfUfCfUmGmAmGfUfJfUAfCf CfUmGfCmG-3T (SEQ ID NO: 1), wherein fC and fU=2′ fluoro nucleotides, mG and mA=2′-OMe nucleotides, all other nucleotides are 2′-OH, and 3T indicates an inverted deoxythymidine.
or a salt thereof.
10 . The method of claim 8 , wherein the subject has intermediate AMD.
11 . The method of claim 8 , wherein the subject has iRORA.
12 . The method of claim 8 , wherein the subject has cRORA
13 . The method of claim 8 , wherein the subject has nGA.
14 . A method for treating an ophthalmological disease, disorder, and/or condition selected from the group consisting of risk factors for the progression to iRORA, iRORA, nGA, intermediate AMD, and cRORA, comprising intravitreally administering a pegylated anti-C5 agent at a dose of about 2 mg/eye to a subject in need thereof,
wherein the pegylated anti-C5 agent is an Aptamer, wherein the Aptamer=fCmGfCfCGfCmGmGfUfCfUfCmAmGmGfCGfCfUmGmAmGfUfCfUmGmAmGfUfUfUAfCf CfUmGfCmG-3T (SEQ ID NO: 1), wherein fC and fU=2′ fluoro nucleotides, mG and mA=2′-OMe nucleotides, all other nucleotides are 2′-OH, and 3T indicates an inverted deoxythymidine.
or a salt thereof.
16 . The method of claim 14 , wherein the subject has intermediate AMD.
17 . The method of claim 14 , wherein the subject has iRORA.
18 . The method of claim 14 , wherein the subject has risk factors for the progression to iRORA.
19 . The method of claim 14 , wherein the subject has nGA.
20 . The method of claim 14 , wherein the subject has cRORA.